Cover - Integrated Performance Report
Meeting: |
Public Board |
Date: |
10.05.2023 |
Report Title: |
Integrated Performance Report |
||
Agenda Item: |
PUB23/4/09 |
||
Author: |
Executive Directors |
||
Lead Director: |
Emma de Carteret, Director of Corporate Affairs and Performance |
SR1a: If we do not ensure our people are safe and their wellbeing prioritised, there is a risk that we will be unable to attract, retain and keep all our people safe and well |
X |
|||||||||||
SR1b: If we do not ensure our leaders are developed and equipped, there is a risk that we will not be able to change our culture, and value, support, develop and grow our people |
X |
|||||||||||
SR2: If we do not deliver operational and clinical standards then there is a risk of poor patient outcomes and experience |
X |
|||||||||||
SR3: If we do not ensure we have the ability to plan, influence and deliver across our systems to secure change, we will not be able to meet the needs of our public and communities |
X |
|||||||||||
SR4: If we do not resolve long standing organisational inefficiencies we will be unable to deliver an effective, sustainable, value for money service to our public |
X |
|||||||||||
SR5: If we do not clearly define our strategic plans we will not have the agility to deliver the suite of improvements needed |
X |
|||||||||||
SR6: If we do not deliver sustainable regulatory compliance and develop positive relationships, we will have limited ability to deliver our strategy |
X | |||||||||||
Equality Impact Assessment |
||||||||||||
No negative impact identified |
X |
|
||||||||||
Recommendation: |
||||||||||||
Note the areas of improvement and decline and seek assurance on plans to improve |
||||||||||||
Previously considered by: |
||||||||||||
Executive Leadership Team |
||||||||||||
Purpose |
||||||||||||
The purpose of this paper is to provide the Integrated Performance Report consisting of March 2023 data. The paper enables the Board to: Discuss the performance areas identified and the actions offered to gain assurance or sufficient oversight. |
||||||||||||
Executive Summary |
||||||||||||
The Integrated Performance Report (IPR) this month comprises of March 2023 data across the key areas of people, education, operations, systems, clinical and finance. Key positives in month are as follows:
Key areas of concern:
In the executive summary slide, the executive team have identified seven critical underlying issues, that impact across multiple measures and therefore our ability to deliver on the organisational objectives. These are as follows:
|
||||||||||||
Introduction/ Background | ||||||||||||
The Integrated Performance report consists of core metrics to monitor the performance across all main functions of the organisation in the pursuit of achievement of our strategic goals. Each of the relevant Executive Directors will provide a short overview of the key critical areas outlined in the section below and in the first executive summary page of the IPR document. | ||||||||||||
Key Issues/ Risks | ||||||||||||
Metric Improvements Board should note that in line with the commitment when the IPR was implemented, a series of refinements will be taking place to a number of metrics within the report. This will address the recognised gaps – including patient transport services, volunteers and integration, as well as amending some of the existing measures in order to enable improved Board monitoring and analysis. The details were circulated to the Board in April and publication is planned in the July report to the Board. |
||||||||||||
Options | ||||||||||||
Note the areas of progress. Consider critical issue areas highlighted to gain assurance on the plans for mitigation |